Bortezomib after allografting in multiple myeloma: association between neurotoxicity and cyclosporine treatment.
Giaccone
Luisa
L
Sorasio
Roberto
R
Patriarca
Francesca
F
Mattei
Daniele
D
Montefusco
Vittorio
V
Peccatori
Jacopo
J
Carnevale-Schianca
Fabrizio
F
Petrucci
Maria Teresa
MT
Milone
Giuseppe
G
Guidi
Stefano
S
Rotta
Marcello
M
Fanin
Renato
R
Corradini
Paolo
P
Boccadoro
Mario
M
Bruno
Benedetto
B
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001897:Boronic Acids / Q000009:adverse effects*; D000069286:Bortezomib; D016572:Cyclosporine / Q000009:adverse effects*; D004347:Drug Interactions; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D009101:Multiple Myeloma / Q000628:therapy*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D011719:Pyrazines / Q000009:adverse effects*; D014184:Transplantation, Homologous
D000970:Antineoplastic Agents; D001897:Boronic Acids; D007166:Immunosuppressive Agents; D011719:Pyrazines; D000069286:Bortezomib; D016572:Cyclosporine